Fig. 6. CD8⁺ T-cell-mediated immune response drives tumor rejection upon challenge.

Corresponding vaccination assay resulting from two methodologies of iDAMP blockade: pharmacological (i.e., celecoxib) and genetic (CRISPR/Cas9 KO). a Tumor volume and b tumor-free survival from the same vaccination assay comparing two methods to deplete PGE₂/iDAMP and their efficacies in affecting drug-induced immunogenic cell death. Corresponding aCD8 mAb treatment results as shown in c, d Vaccine groups: gem (n = 7); gemCelex (n = 8); gemCox-2^−/− (n = 15); gem/aCD8 (n = 4); gemCelex/aCD8 (n = 4); gemCox-2^−/−/aCD8 (n = 5). Statistics: two-tailed, two-way ANOVA-Tukey’s multiple comparisons test (a; **p < 0.0028, ***p < 0.0006, and ****p < 0.0001) and (c; p = 0.0452); Kaplan–Meier survival analysis using Mantel–Cox test (b; p < 0.0001); and where appropriate, data are presented as mean values ±SEM.